So, FINE-ONE answers a question we have been circling for years
ABSTRACT: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 RAs are common therapies for managing diabetes and obesity, but gastrointestinal (GI) adverse effects (AEs) such as nausea, vomiting, diarrhea, and constipation frequently limit therapy
Your Questions Answered GLP-1 Drug Injury FAQs If you experience serious or unexpected side effects, seek medical care right away and follow your healthcare providers guidance
In a recent LinkedIn poll conducted in South Africa, many pharmacists reported that the supply of GLP-1 treatments such as Ozempic is still disrupted, making it challenging for diabetic patients to access the medication they need
Triglycerides decrease, often by 20 to 40%